Ms. Eunhui Chu has specialized in a broad range of intellectual property matters since qualifying as a Korean Patent Attorney in 2000, and currently serves as a Partner at LEE & MOCK IP. Her practice encompasses domestic and international patent prosecution, Office Action (OA) responses, prior-art searches and patentability assessments, patent trials and litigation, freedom-to-operate (FTO) analyses, infringement analyses, IP consulting, and patent landscape analyses.
Ms. Chu’s primary areas of expertise include pharmaceuticals, biotechnology, chemistry, cosmetics, and food products. She handled a substantial number of international patent filings and global patent portfolio management matters, working closely with foreign associates to advise clients on international patent strategies, country-specific filing and prosecution matters, and global IP risk management.
In addition, Ms. Chu specializes in pharmaceutical-related trials and litigation, pharmaceutical patent listing, patent term extension, and trial strategies for securing first generic exclusivity.
She currently serves as an Expert Member of the Central Pharmaceutical Affairs Deliberation Committee.
EDUCATION
- Franklin Pierce Law Center, University of New Hampshire USA (LL.M., 2018)
- Chungnam National University (B.S. in Pharmacy, summa cum laude, 1997)
WORK EXPERIENCE
- LEE & MOCK IP (2001-Present)
- Central Pharmaceutical Affairs Deliberation Committee, Expert (2020-2022; 2024-Present)
- Sughrue Mion, Washington D.C. Office (June 2018-March 2019)
- Hanmi Pharmaceutical Co., Ltd. (1997-1998)
ADMISSION
- Passed the U.S. Patent Agent Examination (2018)
- Patent Attorney, Republic of Korea (2000)
- Pharmacist, Republic of Korea (1997)
LANGUAGES
- Korean, English, Japanese
KEY ACTIVITIES
MEMBERSHIP
- Korean Patent Attorney Association (KPAA)
- International Trademark Association(INTA)
REPRESENTATIVE MATTERS
- - Invalidation Trial for a patent regarding a pharmaceutical composition for treating gastric ulcer (Company D vs. Company N et al.) — successful outcome
- - Invalidation Trial for a patent regarding adipose-derived stem cells (University P vs. Company R) — prevailed at the Supreme Court
- - Invalidation Trial for a patent regarding polymorphic forms of rifaximin (Company A vs. Company H et al.) — successful outcome
- - Invalidation Trial for a patent on medical use of dapoxetine (Company M vs. Company H et al.) — successful outcome
- - Invalidation Trial for a patent on allulose syrup compositions (Company T vs. Company S et al.) — successful outcome
- - Scope Confirmation Trial for a patent regarding a pharmaceutical formulation containing deferasirox (Company N vs. Company G) — successful outcome
- - Scope Confirmation Trial for linagliptin-containing formulations (Company K vs. Company B) — successful outcome
REPRESENTATIVE LITIGATION CASES
- - Patent prosecution and analysis for new drug and formulation technology for Company J (2024–Present)
- - Patent prosecution and analysis for mRNA cap analog technology for Company H (2021–Present)
- - Patent prosecution and analysis for new drug and formulation technology for Company H (2014–2020)
- - Patent prosecution and analysis for new drug for various domestic and international clients (2001–Present)
- - Patent prosecution and analysis for formulation technology for various domestic and international clients (2001–Present)
- - IP education and training programs for pharmaceutical companies and research institutes